Nagahiro Saijo

Papers

Total Citations

H-Index

About

Nagahiro Saijo is a leading figure in thoracic oncology and cancer therapeutics, whose research has fundamentally shaped the treatment of lung cancer. His key contributions span the clinical development of molecularly targeted agents, particularly epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors like gefitinib, and the advancement of personalized medicine in oncology. Saijo’s work was instrumental in establishing the predictive value of EGFR mutations for treatment response, a paradigm-shifting discovery that transformed non-small cell lung cancer management. With a career yielding over 500 publications and more than 20,000 citations, his impact is immense. He has been a principal investigator in pivotal clinical trials, including the landmark NEJ002 study, which demonstrated the superiority of gefitinib over chemotherapy in EGFR-mutant patients. Saijo has also contributed to the development of anti-angiogenic therapies and has served as a key opinion leader in the Japanese Lung Cancer Society. His research continues to guide the integration of biomarkers into routine clinical practice, making him a foundational figure in precision oncology.